数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Neal Walker Director 53 17.55万美元 未持股 2023-05-09
Nancy Miller Rich Director 64 17.55万美元 未持股 2023-05-09
Richard H. Douglas Director,Chairman 70 22.59万美元 未持股 2023-05-09
Martin J. Joyce Director 69 19.82万美元 未持股 2023-05-09
Gary Phillips Director 57 19.65万美元 未持股 2023-05-09
Todd C. Brady President and Chief Executive Officer,Director 51 285.85万美元 未持股 2023-05-09
Ben R. Bronstein Director 73 19.27万美元 未持股 2023-05-09

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Stephen G. Machatha Chief Development Officer 46 256.52万美元 未持股 2023-05-09
Bruce Greenberg Senior Vice President Finance, Interim Chief Financial Officer 55 148.21万美元 未持股 2023-05-09
Todd C. Brady President and Chief Executive Officer,Director 51 285.85万美元 未持股 2023-05-09

董事简历

中英对照 |  中文 |  英文
Neal Walker

Neal Walker联合创立了公司并担任总裁和首席执行官,2012年7月公司成立起担任董事会成员。Walker博士联合创立了NeXeption有限责任公司(NeXeption, LLC,一家生物制药资产管理公司,在2012年8月)。在2011年7月-2012年7月,Walker博士担任许多制药公司的顾问。Walker博士联合创立Vicept Therapeutics股份有限公司(Vicept Therapeutics, Inc.,一家皮肤科专业制药公司)并担任总裁、首席执行官和董事会成员(2009年-2011年7月被Allergan股份有限公司(Allergan, Inc.)收购。先前,Walker先生联合创立并领导许多生命科学公司,包括Octagon Research Solutions股份有限公司(Octagon Research Solutions, Inc.,一家给生物制药公司提供软件和服务的公司,被Accenture plc收购)、Trigenesis Therapeutics股份有限公司(Trigenesis Therapeutics, Inc.,一家专业皮肤科公司,并担任医疗总监(被Dr. Reddy's Laboratories股份有限公司(Dr. Reddy's Laboratories Inc.)收购))和Cutix 股份有限公司(Cutix Inc.一家商业皮肤病公司)。他在Johnson and Johnson股份有限公司(Johnson and Johnson, Inc.)开始他在制药行业的生涯。他是Alderya Therapeutics股份有限公司(Alderya Therapeutics, Inc,一家上市生物技术公司)和几家私人生物技术公司的董事。Walker博士拥有宾夕法尼亚大学沃顿商学院(Wharton School, University of Pennsylvania)工商管理硕士学位、费城正骨疗法医学院(Philadelphia College of Osteopathic Medicine)博士学位和利哈伊大学(Lehigh University)生物学士学位。


Neal Walker,has served on Aldeyra Therapeutics, Inc. Board since June 2013. Dr. Walker is the Chair of the board of directors at Aclaris Therapeutics, Inc., a publicly-traded drug development company, having previously served as President and Chief Executive Officer until December 2022. He is a board certified dermatologist and serial entrepreneur with over 25 years of experience in the biopharmaceutical industry. Prior to founding Aclaris Therapeutics, Inc. in 2012, he was co-founder, President and CEO of Vicept Therapeutics, Inc. (acquired by Allergan, Inc.) from 2009 to 2012. Dr. Walker has co-founded and led a number of life science companies: Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc); Trigenesis Therapeutics, Inc., a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Ltd); and Cutix Inc., a commercial dermatology company that markets PreSun, a sunscreen brand acquired from Bristol-Myers Squibb Co. He began his pharmaceutical industry career at Johnson & Johnson, Inc. In addition to Aclaris, Dr. Walker currently is also on the board of directors of Zoomi, Inc, and Myota, Inc. Dr. Walker previously served on the board of directors for Octagon, a contract research organization. He is also on the Advisory Board of Flexible Medical Systems LLC, a privately held medical device company. Dr. Walker received his M.B.A. from The Wharton School of the University of Pennsylvania, his D.O. from Philadelphia College of Osteopathic Medicine, and a B.A. in Biology from Lehigh University.
Neal Walker联合创立了公司并担任总裁和首席执行官,2012年7月公司成立起担任董事会成员。Walker博士联合创立了NeXeption有限责任公司(NeXeption, LLC,一家生物制药资产管理公司,在2012年8月)。在2011年7月-2012年7月,Walker博士担任许多制药公司的顾问。Walker博士联合创立Vicept Therapeutics股份有限公司(Vicept Therapeutics, Inc.,一家皮肤科专业制药公司)并担任总裁、首席执行官和董事会成员(2009年-2011年7月被Allergan股份有限公司(Allergan, Inc.)收购。先前,Walker先生联合创立并领导许多生命科学公司,包括Octagon Research Solutions股份有限公司(Octagon Research Solutions, Inc.,一家给生物制药公司提供软件和服务的公司,被Accenture plc收购)、Trigenesis Therapeutics股份有限公司(Trigenesis Therapeutics, Inc.,一家专业皮肤科公司,并担任医疗总监(被Dr. Reddy's Laboratories股份有限公司(Dr. Reddy's Laboratories Inc.)收购))和Cutix 股份有限公司(Cutix Inc.一家商业皮肤病公司)。他在Johnson and Johnson股份有限公司(Johnson and Johnson, Inc.)开始他在制药行业的生涯。他是Alderya Therapeutics股份有限公司(Alderya Therapeutics, Inc,一家上市生物技术公司)和几家私人生物技术公司的董事。Walker博士拥有宾夕法尼亚大学沃顿商学院(Wharton School, University of Pennsylvania)工商管理硕士学位、费城正骨疗法医学院(Philadelphia College of Osteopathic Medicine)博士学位和利哈伊大学(Lehigh University)生物学士学位。
Neal Walker,has served on Aldeyra Therapeutics, Inc. Board since June 2013. Dr. Walker is the Chair of the board of directors at Aclaris Therapeutics, Inc., a publicly-traded drug development company, having previously served as President and Chief Executive Officer until December 2022. He is a board certified dermatologist and serial entrepreneur with over 25 years of experience in the biopharmaceutical industry. Prior to founding Aclaris Therapeutics, Inc. in 2012, he was co-founder, President and CEO of Vicept Therapeutics, Inc. (acquired by Allergan, Inc.) from 2009 to 2012. Dr. Walker has co-founded and led a number of life science companies: Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc); Trigenesis Therapeutics, Inc., a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Ltd); and Cutix Inc., a commercial dermatology company that markets PreSun, a sunscreen brand acquired from Bristol-Myers Squibb Co. He began his pharmaceutical industry career at Johnson & Johnson, Inc. In addition to Aclaris, Dr. Walker currently is also on the board of directors of Zoomi, Inc, and Myota, Inc. Dr. Walker previously served on the board of directors for Octagon, a contract research organization. He is also on the Advisory Board of Flexible Medical Systems LLC, a privately held medical device company. Dr. Walker received his M.B.A. from The Wharton School of the University of Pennsylvania, his D.O. from Philadelphia College of Osteopathic Medicine, and a B.A. in Biology from Lehigh University.
Nancy Miller Rich

Nancy Miller Rich自2020年11月以来一直担任我们的董事会成员。她自2017年9月起担任多家制药和生物技术公司的顾问和顾问。此前,米勒-里奇曾在默克制药公司担任过多个领导职务,在两家公司合并之前,她曾在Schering-PloughCorporation担任过多个领导职务,包括最近担任高级副总裁,全球人类健康业务开发与许可部门的职务,2013年11月至2017年9月提供战略和商业支持,2007年1月至2013年11月担任集团Vice President,Consumer Care Global New Ventures和战略商业开发。1990年加入Schering-Plough之前,Miller-Rich在Sandoz Pharmaceuticals和Sterling Drug,Inc.担任多个商业和营销职位。Miller-Rich女士曾担任多家上市生物技术公司的董事会成员,例如自2018年4月以来担任InterceptPharmaceuticals,Inc.董事,自2020年1月以来担任AldeyraTherapeutics,Inc.董事,自2020年10月以来担任KadmonHoldings,Inc.董事。她于1981年获得纽约伊萨卡学院(Ithaca College)的工商管理营销本科学位。


Nancy Miller Rich,has been a member of Aldeyra Therapeutics, Inc. Board since January 2020. She is Chief Executive of Miller-Rich Associates, a pharmaceutical industry consultancy she founded in 2017. Previously, she served as Senior Vice-President, Global Human Health Business Development & Licensing, Strategy and Commercial Support at Merck Pharmaceuticals. At Merck, Ms. Miller-Rich had direct P&L involvement in the $38 billion pharmaceutical division and closed approximately 300 deals producing $10 billion of value creation. Prior to Merck, she worked for Schering-Plough Corporation, where she was Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support from 2013 to 2017 and Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development from 2007 to 2013. Prior to joining Schering-Plough in 1990, Ms. Miller-Rich served in a variety of commercial and marketing roles at Sandoz Pharmaceuticals and Sterling Drug, Inc. She is a director of Intercept Pharmaceuticals, Inc. and 4D Molecular Therapeutics, Inc., and previously served as a director of Kadmon Holdings. Ms. Miller-Rich also serves as a board member of a number of private and not-for-profit entities. Ms. Miller-Rich received her B.S. in Business Administration, Marketing from Ithaca College in Ithaca, New York.
Nancy Miller Rich自2020年11月以来一直担任我们的董事会成员。她自2017年9月起担任多家制药和生物技术公司的顾问和顾问。此前,米勒-里奇曾在默克制药公司担任过多个领导职务,在两家公司合并之前,她曾在Schering-PloughCorporation担任过多个领导职务,包括最近担任高级副总裁,全球人类健康业务开发与许可部门的职务,2013年11月至2017年9月提供战略和商业支持,2007年1月至2013年11月担任集团Vice President,Consumer Care Global New Ventures和战略商业开发。1990年加入Schering-Plough之前,Miller-Rich在Sandoz Pharmaceuticals和Sterling Drug,Inc.担任多个商业和营销职位。Miller-Rich女士曾担任多家上市生物技术公司的董事会成员,例如自2018年4月以来担任InterceptPharmaceuticals,Inc.董事,自2020年1月以来担任AldeyraTherapeutics,Inc.董事,自2020年10月以来担任KadmonHoldings,Inc.董事。她于1981年获得纽约伊萨卡学院(Ithaca College)的工商管理营销本科学位。
Nancy Miller Rich,has been a member of Aldeyra Therapeutics, Inc. Board since January 2020. She is Chief Executive of Miller-Rich Associates, a pharmaceutical industry consultancy she founded in 2017. Previously, she served as Senior Vice-President, Global Human Health Business Development & Licensing, Strategy and Commercial Support at Merck Pharmaceuticals. At Merck, Ms. Miller-Rich had direct P&L involvement in the $38 billion pharmaceutical division and closed approximately 300 deals producing $10 billion of value creation. Prior to Merck, she worked for Schering-Plough Corporation, where she was Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support from 2013 to 2017 and Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development from 2007 to 2013. Prior to joining Schering-Plough in 1990, Ms. Miller-Rich served in a variety of commercial and marketing roles at Sandoz Pharmaceuticals and Sterling Drug, Inc. She is a director of Intercept Pharmaceuticals, Inc. and 4D Molecular Therapeutics, Inc., and previously served as a director of Kadmon Holdings. Ms. Miller-Rich also serves as a board member of a number of private and not-for-profit entities. Ms. Miller-Rich received her B.S. in Business Administration, Marketing from Ithaca College in Ithaca, New York.
Richard H. Douglas

Richard H. Douglas, 他是Genzyme Corporation的前公司发展高级副总裁。从1989年至2011年,他领导Genzyme Corporation的公司发展团队,并参与多个收购、授权、融资、合资和战略联盟。从1982年起至1989年与Genzyme Corporation合并,他在Integrated Genetics科学与公司发展部门工作。他曾在加州理工学院(California Institute of Technology)勒罗伊胡德实验室担任博士后研究员。他是密歇根大学(University of Michigan)技术转让国家咨询委员会成员。他在加利福尼亚大学(University of California)伯克利分校获得生物化学博士学位,并在密歇根大学(University of Michigan)获得化学学士学位。


Richard H. Douglas,has served on Aldeyra Therapeutics, Inc. Board since September 2016. Dr. Douglas was formerly Senior Vice President, Corporate Development of Genzyme Corporation. From 1989 to 2011, he led Genzyme Corporation's Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Currently, Dr. Douglas is on the board of directors of Novavax, Inc., a publicly-traded clinical-stage vaccine company; MaxCyte, Inc., a publicly traded instrument and immunotherapeutic company; and the University of Michigan Technology Transfer National Advisory Board. Dr. Douglas received a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley, and he was a postdoctoral fellow in Leroy Hood's laboratory at the California Institute of Technology.
Richard H. Douglas, 他是Genzyme Corporation的前公司发展高级副总裁。从1989年至2011年,他领导Genzyme Corporation的公司发展团队,并参与多个收购、授权、融资、合资和战略联盟。从1982年起至1989年与Genzyme Corporation合并,他在Integrated Genetics科学与公司发展部门工作。他曾在加州理工学院(California Institute of Technology)勒罗伊胡德实验室担任博士后研究员。他是密歇根大学(University of Michigan)技术转让国家咨询委员会成员。他在加利福尼亚大学(University of California)伯克利分校获得生物化学博士学位,并在密歇根大学(University of Michigan)获得化学学士学位。
Richard H. Douglas,has served on Aldeyra Therapeutics, Inc. Board since September 2016. Dr. Douglas was formerly Senior Vice President, Corporate Development of Genzyme Corporation. From 1989 to 2011, he led Genzyme Corporation's Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Currently, Dr. Douglas is on the board of directors of Novavax, Inc., a publicly-traded clinical-stage vaccine company; MaxCyte, Inc., a publicly traded instrument and immunotherapeutic company; and the University of Michigan Technology Transfer National Advisory Board. Dr. Douglas received a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley, and he was a postdoctoral fellow in Leroy Hood's laboratory at the California Institute of Technology.
Martin J. Joyce

Martin J. Joyce自从2013年10月起担任董事会成员。Joyce先生的专业背景包括公共和私人领导角色,医疗设备、生物技术和制药公司,在初创阶段年收入超过5亿美元。他拥有公共股本融资、业务发展、SEC报告、战略规划、合并、收购、投资者关系和生物技术操作等方面的经验。2012年起,Joyce先生担任生命科学产业顾问,负责协助生物技术和制药公司的策略规划、筹集资金以及运营。2011年3月至2012年7月,Joyce先生是Lucid公司的首席财务官,该公司是一家早期皮肤癌诊断公司。在此之前,2006年1月至2010年9月,他是BioSphere医疗公司的执行副总裁和首席财务官。2001年1月至2004年9月,Joyce是Stratex集团有限责任公司的管理合伙人,生物制药早期企业行政服务供应商和风险投资者。1996年至2001年1月,Joyce是生物科技Serono公司北美地区的首席财务官。1987年至1996年,Joyce在Serono公司担任了包括金融、销售营销及制造在内的多个职务。最初,他受雇于一家高科技生物科学公司——Millipore Corporation。Joyce在东北大学获得金融学士学位,在马萨诸塞州波士顿的萨福克大学获得MBA学位。


Martin J. Joyce,has served as member of Aldeyra Therapeutics, Inc. Board since October 2013. Mr. Joyce's professional background includes leadership roles in public and private, medical device, biotechnology, and pharmaceutical companies from start-up stage to over $500 million in annual revenue. He has experience in public equity financings, business development, SEC reporting, strategic planning, mergers, acquisitions, investor relations, and biotechnology operations. Since 2012, Mr. Joyce has served as a consultant to the life science industry assisting biotechnology and pharmaceutical companies in strategic planning, fund raising, and operations. From March 2011 to July 2012, Mr. Joyce was Chief Financial Officer at Lucid Inc., an early stage skin cancer diagnostic company. Previously, Mr. Joyce served as Executive Vice President and Chief Financial Officer of BioSphere Medical from January 2006 through September 2010 and as BioSphere's Chief Financial Officer and Vice President from September 2004 to January 2006. From January 2001 to September 2004, Mr. Joyce served as Managing Partner of Stratex Group LLC, a provider of biopharmaceutical executive services to early-stage companies and venture investors. From 1996 to January 2001, Mr. Joyce was North American Chief Financial Officer for Serono Inc. a biotechnology company. From April 1987 to 1996, Mr. Joyce held a variety of senior level positions within Serono in finance, sales, marketing and manufacturing. Mr. Joyce was previously employed at Millipore Corporation, a high technology bioscience company. Mr. Joyce received a B.S. in finance from Northeastern University and a M.B.A. from Suffolk University, Boston, Massachusetts.
Martin J. Joyce自从2013年10月起担任董事会成员。Joyce先生的专业背景包括公共和私人领导角色,医疗设备、生物技术和制药公司,在初创阶段年收入超过5亿美元。他拥有公共股本融资、业务发展、SEC报告、战略规划、合并、收购、投资者关系和生物技术操作等方面的经验。2012年起,Joyce先生担任生命科学产业顾问,负责协助生物技术和制药公司的策略规划、筹集资金以及运营。2011年3月至2012年7月,Joyce先生是Lucid公司的首席财务官,该公司是一家早期皮肤癌诊断公司。在此之前,2006年1月至2010年9月,他是BioSphere医疗公司的执行副总裁和首席财务官。2001年1月至2004年9月,Joyce是Stratex集团有限责任公司的管理合伙人,生物制药早期企业行政服务供应商和风险投资者。1996年至2001年1月,Joyce是生物科技Serono公司北美地区的首席财务官。1987年至1996年,Joyce在Serono公司担任了包括金融、销售营销及制造在内的多个职务。最初,他受雇于一家高科技生物科学公司——Millipore Corporation。Joyce在东北大学获得金融学士学位,在马萨诸塞州波士顿的萨福克大学获得MBA学位。
Martin J. Joyce,has served as member of Aldeyra Therapeutics, Inc. Board since October 2013. Mr. Joyce's professional background includes leadership roles in public and private, medical device, biotechnology, and pharmaceutical companies from start-up stage to over $500 million in annual revenue. He has experience in public equity financings, business development, SEC reporting, strategic planning, mergers, acquisitions, investor relations, and biotechnology operations. Since 2012, Mr. Joyce has served as a consultant to the life science industry assisting biotechnology and pharmaceutical companies in strategic planning, fund raising, and operations. From March 2011 to July 2012, Mr. Joyce was Chief Financial Officer at Lucid Inc., an early stage skin cancer diagnostic company. Previously, Mr. Joyce served as Executive Vice President and Chief Financial Officer of BioSphere Medical from January 2006 through September 2010 and as BioSphere's Chief Financial Officer and Vice President from September 2004 to January 2006. From January 2001 to September 2004, Mr. Joyce served as Managing Partner of Stratex Group LLC, a provider of biopharmaceutical executive services to early-stage companies and venture investors. From 1996 to January 2001, Mr. Joyce was North American Chief Financial Officer for Serono Inc. a biotechnology company. From April 1987 to 1996, Mr. Joyce held a variety of senior level positions within Serono in finance, sales, marketing and manufacturing. Mr. Joyce was previously employed at Millipore Corporation, a high technology bioscience company. Mr. Joyce received a B.S. in finance from Northeastern University and a M.B.A. from Suffolk University, Boston, Massachusetts.
Gary Phillips

Gary Phillips,曾担任Aldeyra Therapeutics, Inc.的成员。2009年5月起担任董事会成员。他曾担任Anaveon AG的首席商务官(2022年5月以来)。在此之前,他于2018年至2022年担任OrphoMed, Inc.的总裁兼首席执行官,并于2013年至2018年担任Mallinckrodt Pharmaceuticals plc的执行副总裁兼首席战略官。此前,他曾担任Bausch & Lomb公司的美国外科和制药总裁以及全球制药主管。此外,他曾担任Geneva世界经济论坛的全球卫生主管,并担任Reckitt Benckiser Pharmaceuticals, Inc.(现为独立)的总裁。他还曾在Merck KGaA、Novartis和Wyeth(现为辉瑞公司)担任高管职务。他曾是Towers Perrin(现为Willis Towers Watson)的医疗保健战略管理顾问,也是美国海军的医务官员,并以中尉指挥官的身份光荣退役。他在University of Pennsylvania接受教育,在那里他获得了医学院的医学博士学位(Alpha Omega Alpha),Wharton商学院的工商管理硕士学位,以及艺术与科学学院的生物化学学士学位(优等生,Phi Beta Kappa)。他在Naval Medical Center San Diego完成了研究生医学教育,并持有有效的医疗执照。


Gary Phillips,has served as a member of Aldeyra Therapeutics, Inc. Board since May 2009. Dr. Phillips has served as Chief Business Officer of Anaveon AG since May 2022. Prior to that, he was President & CEO of OrphoMed, Inc. from 2018 to 2022 and Executive Vice President & Chief Strategy Officer at Mallinckrodt Pharmaceuticals plc from 2013 to 2018. Previously, Dr. Phillips held the dual roles of president, U.S. surgical and pharmaceuticals and global head of pharmaceuticals at Bausch & Lomb. Additionally, he has served as the head of global health at the World Economic Forum in Geneva and was president of Reckitt Benckiser Pharmaceuticals, Inc. (now Indivior). He has also held executive roles at Merck KGaA, Novartis, and Wyeth (now Pfizer). He was a healthcare strategy managing consultant at Towers Perrin (now Willis Towers Watson) and a medical officer with the United States Navy, from which he was honorably discharged as a lieutenant commander. Dr. Phillips was educated at the University of Pennsylvania, where he received an M.D. (Alpha Omega Alpha) from the School of Medicine, an M.B.A. from the Wharton School, and B.A. (summa cum laude, Phi Beta Kappa) in biochemistry from the College of Arts and Sciences. He completed postgraduate medical education at Naval Medical Center San Diego and maintains an active medical license.
Gary Phillips,曾担任Aldeyra Therapeutics, Inc.的成员。2009年5月起担任董事会成员。他曾担任Anaveon AG的首席商务官(2022年5月以来)。在此之前,他于2018年至2022年担任OrphoMed, Inc.的总裁兼首席执行官,并于2013年至2018年担任Mallinckrodt Pharmaceuticals plc的执行副总裁兼首席战略官。此前,他曾担任Bausch & Lomb公司的美国外科和制药总裁以及全球制药主管。此外,他曾担任Geneva世界经济论坛的全球卫生主管,并担任Reckitt Benckiser Pharmaceuticals, Inc.(现为独立)的总裁。他还曾在Merck KGaA、Novartis和Wyeth(现为辉瑞公司)担任高管职务。他曾是Towers Perrin(现为Willis Towers Watson)的医疗保健战略管理顾问,也是美国海军的医务官员,并以中尉指挥官的身份光荣退役。他在University of Pennsylvania接受教育,在那里他获得了医学院的医学博士学位(Alpha Omega Alpha),Wharton商学院的工商管理硕士学位,以及艺术与科学学院的生物化学学士学位(优等生,Phi Beta Kappa)。他在Naval Medical Center San Diego完成了研究生医学教育,并持有有效的医疗执照。
Gary Phillips,has served as a member of Aldeyra Therapeutics, Inc. Board since May 2009. Dr. Phillips has served as Chief Business Officer of Anaveon AG since May 2022. Prior to that, he was President & CEO of OrphoMed, Inc. from 2018 to 2022 and Executive Vice President & Chief Strategy Officer at Mallinckrodt Pharmaceuticals plc from 2013 to 2018. Previously, Dr. Phillips held the dual roles of president, U.S. surgical and pharmaceuticals and global head of pharmaceuticals at Bausch & Lomb. Additionally, he has served as the head of global health at the World Economic Forum in Geneva and was president of Reckitt Benckiser Pharmaceuticals, Inc. (now Indivior). He has also held executive roles at Merck KGaA, Novartis, and Wyeth (now Pfizer). He was a healthcare strategy managing consultant at Towers Perrin (now Willis Towers Watson) and a medical officer with the United States Navy, from which he was honorably discharged as a lieutenant commander. Dr. Phillips was educated at the University of Pennsylvania, where he received an M.D. (Alpha Omega Alpha) from the School of Medicine, an M.B.A. from the Wharton School, and B.A. (summa cum laude, Phi Beta Kappa) in biochemistry from the College of Arts and Sciences. He completed postgraduate medical education at Naval Medical Center San Diego and maintains an active medical license.
Todd C. Brady

Todd C. Brady自2012年1月起担任Aldeyra Therapeutics,Inc.总裁兼首席执行官,自2005年起成为Aldeyla Therapeunics,Inc.董事会成员。加入Aldeyra之前,他曾担任Domain Associates, LLC(一家领先的医疗风险投资公司)的常驻企业家,从2004年到2013年担任负责人。他目前担任Evoke Pharma, Inc.(一家公开交易的医疗保健公司)的董事会成员。他持有Duke University研究生院的病理学博士学位,Duke University医学院的医学博士学位,以及Dartmouth College的哲学和心理学学士学位。


Todd C. Brady,has served as Aldeyra Therapeutics, Inc. President and Chief Executive Officer since January of 2012 and as a member of Aldeyra Therapeutics, Inc. Board since 2005. Prior to Aldeyra, Dr. Brady served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady currently serves on the board of directors of Evoke Pharma, Inc., a publicly traded healthcare company. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, a M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology.
Todd C. Brady自2012年1月起担任Aldeyra Therapeutics,Inc.总裁兼首席执行官,自2005年起成为Aldeyla Therapeunics,Inc.董事会成员。加入Aldeyra之前,他曾担任Domain Associates, LLC(一家领先的医疗风险投资公司)的常驻企业家,从2004年到2013年担任负责人。他目前担任Evoke Pharma, Inc.(一家公开交易的医疗保健公司)的董事会成员。他持有Duke University研究生院的病理学博士学位,Duke University医学院的医学博士学位,以及Dartmouth College的哲学和心理学学士学位。
Todd C. Brady,has served as Aldeyra Therapeutics, Inc. President and Chief Executive Officer since January of 2012 and as a member of Aldeyra Therapeutics, Inc. Board since 2005. Prior to Aldeyra, Dr. Brady served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady currently serves on the board of directors of Evoke Pharma, Inc., a publicly traded healthcare company. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, a M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology.
Ben R. Bronstein

Ben R. Bronstein在Aldeyra Therapeutics(之后称之为Neuron Systems)自2010年起是董事会成员,2010年至2011年担任首席执行官。Bronstein是 哈佛大学医学院Wyss生物工程机构的访问学者,也是生命科学公司的活跃顾问。他是通过资格验证的病理学家,拥有20多篇发表作品。Bronstein的职业生涯源于在麻省综合医院做医生和哈佛医学院做教师。他在生命科学公司及风险投资公司担了25年的企业家角色,在包括 BioSurface Technologies Corporation(医药再生公司)、Peptimmune(由哈佛和麻省理工学院衍生而出)、Vidus Ocular(耶鲁大学开发一种用以治疗青光眼植入式装置)等风险资本支持的公司。最近,他是Access BridgeGap Ventures创始人及高级副总裁,在多个私人生命科学公司担任董事会成员。他也是威尔康奈尔医学院教师行业委员会的成员以及波士顿大学Coulte监督委员会成员。Bronstein在波士顿大学获得医学博士学位和工商管理学硕士学位。


Ben R. Bronstein,has served as a member of Aldeyra Therapeutics, Inc. Board since 2010. Since 1999, Dr. Bronstein has been an independent consultant providing advisory services to companies in the life sciences industry. From 2017 to 2018, Dr. Bronstein served as Executive Vice President, Clinical Development at Aclaris Therapeutics, Inc. Prior to his time at Aclaris, Dr. Bronstein served as the interim Chief Medical Officer at Sentien Biotechnologies, Inc. from 2016 to 2017. Dr. Bronstein is a board-certified pathologist and dermatopathologist, with over 20 publications. Dr. Bronstein began his professional career on the staff of the Massachusetts General Hospital and on the faculty of Harvard Medical School. He has spent the past 33 years in entrepreneurial and management roles in life science companies and venture capital firms. Dr. Bronstein has founded or held senior management positions at several venture-backed life science companies including: Aldeyra; BioSurface Technology, Inc., a regenerative medicine company; Peptimmune, Inc., an immunotherapeutics company (a spinout from Harvard and MIT); and Vidus Ocular, Inc., a Yale University spinout developing an implantable device for the treatment of glaucoma. Dr. Bronstein has served as Chief Medical Officer of Stealth BioTherapeutics, Inc., as a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard Medical School, and as a founder and Senior Vice President of Access BridgeGap Ventures, the life science investment unit of Access Industries, Inc. Dr. Bronstein serves on the board of directors of Cleveland Diagnostics, Inc. where he is non-executive chair. Dr. Bronstein received his M.D. and M.B.A. from Boston University.
Ben R. Bronstein在Aldeyra Therapeutics(之后称之为Neuron Systems)自2010年起是董事会成员,2010年至2011年担任首席执行官。Bronstein是 哈佛大学医学院Wyss生物工程机构的访问学者,也是生命科学公司的活跃顾问。他是通过资格验证的病理学家,拥有20多篇发表作品。Bronstein的职业生涯源于在麻省综合医院做医生和哈佛医学院做教师。他在生命科学公司及风险投资公司担了25年的企业家角色,在包括 BioSurface Technologies Corporation(医药再生公司)、Peptimmune(由哈佛和麻省理工学院衍生而出)、Vidus Ocular(耶鲁大学开发一种用以治疗青光眼植入式装置)等风险资本支持的公司。最近,他是Access BridgeGap Ventures创始人及高级副总裁,在多个私人生命科学公司担任董事会成员。他也是威尔康奈尔医学院教师行业委员会的成员以及波士顿大学Coulte监督委员会成员。Bronstein在波士顿大学获得医学博士学位和工商管理学硕士学位。
Ben R. Bronstein,has served as a member of Aldeyra Therapeutics, Inc. Board since 2010. Since 1999, Dr. Bronstein has been an independent consultant providing advisory services to companies in the life sciences industry. From 2017 to 2018, Dr. Bronstein served as Executive Vice President, Clinical Development at Aclaris Therapeutics, Inc. Prior to his time at Aclaris, Dr. Bronstein served as the interim Chief Medical Officer at Sentien Biotechnologies, Inc. from 2016 to 2017. Dr. Bronstein is a board-certified pathologist and dermatopathologist, with over 20 publications. Dr. Bronstein began his professional career on the staff of the Massachusetts General Hospital and on the faculty of Harvard Medical School. He has spent the past 33 years in entrepreneurial and management roles in life science companies and venture capital firms. Dr. Bronstein has founded or held senior management positions at several venture-backed life science companies including: Aldeyra; BioSurface Technology, Inc., a regenerative medicine company; Peptimmune, Inc., an immunotherapeutics company (a spinout from Harvard and MIT); and Vidus Ocular, Inc., a Yale University spinout developing an implantable device for the treatment of glaucoma. Dr. Bronstein has served as Chief Medical Officer of Stealth BioTherapeutics, Inc., as a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard Medical School, and as a founder and Senior Vice President of Access BridgeGap Ventures, the life science investment unit of Access Industries, Inc. Dr. Bronstein serves on the board of directors of Cleveland Diagnostics, Inc. where he is non-executive chair. Dr. Bronstein received his M.D. and M.B.A. from Boston University.

高管简历

中英对照 |  中文 |  英文
Stephen G. Machatha

Stephen G.MacHatha自2019年1月起担任我们的高级副总裁,技术运营。马哈塔博士于2016年加入Aldeyra,担任化学制造和控制Vice President。在加入Aldeyra之前,2014年1月至2015年12月,马哈塔博士担任Synageva Biopharmaceuticals(一家被Alexion Pharmaceuticals收购的生物技术公司)的化学制造和控制以及药物产品开发总监。MacHatha博士领导化学制造和控制团队,参与Kanumatm Sebelipase Alfa的开发和监管备案。在Synageva工作之前,Machata博士在Cubist Pharmaceuticals(被Merck&Co.收购)和Cydex Pharmaceuticals(被Ligand Pharmaceuticals收购)担任越来越重要的科学和产品开发职务。他曾就读于亚利桑那大学(the University of Arizona),在那里他获得制药科学博士学位、化学硕士学位和工商管理硕士学位。在化学方面。


Stephen G. Machatha,joined Aldeyra in January 2016 as Vice President of Chemistry Manufacturing and Controls, was later appointed as Senior Vice President of Technical Operations in January 2019, and subsequently, Chief Development Officer in January 2021. Prior to joining Aldeyra, Dr. Machatha held scientific and product development roles of increasing responsibilities at Synageva Biopharmaceuticals (acquired by Alexion Pharmaceuticals), Cubist Pharmaceuticals (acquired by Merck & Co.), and CyDex Pharmaceuticals (acquired by Ligand Pharmaceuticals). Dr. Machatha attended the University of Arizona, where he received a Ph.D. in Pharmaceutical Sciences, an M.A. in Chemistry, and a B.Sc. in Chemistry.
Stephen G.MacHatha自2019年1月起担任我们的高级副总裁,技术运营。马哈塔博士于2016年加入Aldeyra,担任化学制造和控制Vice President。在加入Aldeyra之前,2014年1月至2015年12月,马哈塔博士担任Synageva Biopharmaceuticals(一家被Alexion Pharmaceuticals收购的生物技术公司)的化学制造和控制以及药物产品开发总监。MacHatha博士领导化学制造和控制团队,参与Kanumatm Sebelipase Alfa的开发和监管备案。在Synageva工作之前,Machata博士在Cubist Pharmaceuticals(被Merck&Co.收购)和Cydex Pharmaceuticals(被Ligand Pharmaceuticals收购)担任越来越重要的科学和产品开发职务。他曾就读于亚利桑那大学(the University of Arizona),在那里他获得制药科学博士学位、化学硕士学位和工商管理硕士学位。在化学方面。
Stephen G. Machatha,joined Aldeyra in January 2016 as Vice President of Chemistry Manufacturing and Controls, was later appointed as Senior Vice President of Technical Operations in January 2019, and subsequently, Chief Development Officer in January 2021. Prior to joining Aldeyra, Dr. Machatha held scientific and product development roles of increasing responsibilities at Synageva Biopharmaceuticals (acquired by Alexion Pharmaceuticals), Cubist Pharmaceuticals (acquired by Merck & Co.), and CyDex Pharmaceuticals (acquired by Ligand Pharmaceuticals). Dr. Machatha attended the University of Arizona, where he received a Ph.D. in Pharmaceutical Sciences, an M.A. in Chemistry, and a B.Sc. in Chemistry.
Bruce Greenberg

布鲁斯·格林伯格于2019年12月加入Aldeyra,担任副总裁兼财务总监,自2022年5月起担任Aldeyra Therapeutics, Inc.临时首席财务官。在加入Aldeyra之前,他于2017年5月至2019年12月担任Karyopharm Therapeutics Inc.的公司财务总监,该公司为Aldeyra Therapeutics公司开发和商业化肿瘤治疗药物。在此之前,他在KVH Industries,Inc.,Berklee College of Music,Harvard Bioscience, Inc.和MKS Instruments公司担任越来越重要的职务。他的职业生涯始于安永会计师事务所的审计业务成员,在那里他专注于生命科学和技术客户。格林伯格是一名注册会计师,他在克拉克大学获得经济学学士学位,在东北大学达莫尔-麦金商学院获得会计学工商管理硕士学位。


Bruce Greenberg,joined Aldeyra in December 2019 as Vice President, Controller, and has served as Aldeyra Therapeutics, Inc. Interim Chief Financial Officer since May 2022.Prior to Aldeyra, from May 2017 to December 2019, he served as the Corporate Controller for Karyopharm Therapeutics Inc., which develops and commercializes drugs for Aldeyra Therapeutics, Inc. e in oncological treatments. Previously, he held positions of increasing responsibility at KVH Industries, Inc., Berklee College of Music, Harvard Bioscience, Inc., and MKS Instruments, Inc. He began his career as a member of the audit practice of Ernst & Young LLP, where he focused on life science and technology clients. Mr. Greenberg, a certified public accountant, received his B.A. in Economics from Clark University and his M.B.A. in Accounting from Northeastern University's D'Amore-McKim School of Business.
布鲁斯·格林伯格于2019年12月加入Aldeyra,担任副总裁兼财务总监,自2022年5月起担任Aldeyra Therapeutics, Inc.临时首席财务官。在加入Aldeyra之前,他于2017年5月至2019年12月担任Karyopharm Therapeutics Inc.的公司财务总监,该公司为Aldeyra Therapeutics公司开发和商业化肿瘤治疗药物。在此之前,他在KVH Industries,Inc.,Berklee College of Music,Harvard Bioscience, Inc.和MKS Instruments公司担任越来越重要的职务。他的职业生涯始于安永会计师事务所的审计业务成员,在那里他专注于生命科学和技术客户。格林伯格是一名注册会计师,他在克拉克大学获得经济学学士学位,在东北大学达莫尔-麦金商学院获得会计学工商管理硕士学位。
Bruce Greenberg,joined Aldeyra in December 2019 as Vice President, Controller, and has served as Aldeyra Therapeutics, Inc. Interim Chief Financial Officer since May 2022.Prior to Aldeyra, from May 2017 to December 2019, he served as the Corporate Controller for Karyopharm Therapeutics Inc., which develops and commercializes drugs for Aldeyra Therapeutics, Inc. e in oncological treatments. Previously, he held positions of increasing responsibility at KVH Industries, Inc., Berklee College of Music, Harvard Bioscience, Inc., and MKS Instruments, Inc. He began his career as a member of the audit practice of Ernst & Young LLP, where he focused on life science and technology clients. Mr. Greenberg, a certified public accountant, received his B.A. in Economics from Clark University and his M.B.A. in Accounting from Northeastern University's D'Amore-McKim School of Business.
Todd C. Brady

Todd C. Brady自2012年1月起担任Aldeyra Therapeutics,Inc.总裁兼首席执行官,自2005年起成为Aldeyla Therapeunics,Inc.董事会成员。加入Aldeyra之前,他曾担任Domain Associates, LLC(一家领先的医疗风险投资公司)的常驻企业家,从2004年到2013年担任负责人。他目前担任Evoke Pharma, Inc.(一家公开交易的医疗保健公司)的董事会成员。他持有Duke University研究生院的病理学博士学位,Duke University医学院的医学博士学位,以及Dartmouth College的哲学和心理学学士学位。


Todd C. Brady,has served as Aldeyra Therapeutics, Inc. President and Chief Executive Officer since January of 2012 and as a member of Aldeyra Therapeutics, Inc. Board since 2005. Prior to Aldeyra, Dr. Brady served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady currently serves on the board of directors of Evoke Pharma, Inc., a publicly traded healthcare company. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, a M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology.
Todd C. Brady自2012年1月起担任Aldeyra Therapeutics,Inc.总裁兼首席执行官,自2005年起成为Aldeyla Therapeunics,Inc.董事会成员。加入Aldeyra之前,他曾担任Domain Associates, LLC(一家领先的医疗风险投资公司)的常驻企业家,从2004年到2013年担任负责人。他目前担任Evoke Pharma, Inc.(一家公开交易的医疗保健公司)的董事会成员。他持有Duke University研究生院的病理学博士学位,Duke University医学院的医学博士学位,以及Dartmouth College的哲学和心理学学士学位。
Todd C. Brady,has served as Aldeyra Therapeutics, Inc. President and Chief Executive Officer since January of 2012 and as a member of Aldeyra Therapeutics, Inc. Board since 2005. Prior to Aldeyra, Dr. Brady served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady currently serves on the board of directors of Evoke Pharma, Inc., a publicly traded healthcare company. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, a M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology.